ArticleJournal of thrombosis and thrombolysis2026
Plasminogen supplementation enhances alteplase fibrinolysis efficacy in a systemic embolization rat model.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Enhancing the fibrinolysis efficacy of recombinant tissue plasminogen activators (r-tPA) may be achieved by increasing the blood plasminogen levels. This study evaluated the effect of plasminogen (PLG) addition to a clinically relevant alteplase (r-tPA) dose on fibrinolysis. Sixty nine Wistar albino rats were divided into 7 groups; control (n = 10), r-tPA 0.9 mg/kg (0.9r-tPA) (n = 10), r-tPA 0.9 mg/kg + PLG 8 IU/kg (0.9r-tPA+8PLG) (n = 10), r-tPA 0.9 mg/kg + PLG 16 IU/kg (0.9r-tPA+16PLG) (n = 10), r-tPA 0.6 mg/kg + PLG 8 IU/kg (0.6r-tPA+8PLG) (n = 10), r-tPA 0.6 mg/kg + PLG 16 IU/kg (0.6r-tPA+16PLG) (n = 10), and r-tPA 0.9 mg/kg + PLG 8 IU/kg (0.9r-tPA+8PLG60) (n = 9) with the PLG administered 60 min before the r-tPA administration. In all groups, systemic embolism was induced by application of three barium sulfate-labeled artificial clots in abdominal aorta. Artificial clots were visualized under micro-fluoroscopy, and radiographs were captured every 5 min during fibrinolytic/saline infusion. The measurement of clot area was used to calculate fibrinolysis rate (%/min) and the area under the curve (AUC; %*min). Results show that all PLG combinations enhanced fibrinolysis relative to untreated controls (p < 0.001). At the clinical 0.9 mg/kg dose, PLG supplementation significantly increased the fibrinolysis rate compared with r-tPA alone (r-tPA: 0.8 ± 0.5%/min; 8 IU/kg, p = 0.025; 16 IU/kg, p < 0.001), and this benefit was retained when PLG was administered 60 min in advance (p = 0.024). Differences between PLG doses were not statistically significant. Systemic plasminogen supplementation therefore enhances r-tPA-mediated fibrinolysis in vivo at a clinically relevant dose and regimen, without requiring catheter-directed delivery.
Indexed as
Identifiers
42631844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.